About MetamarkMetamark Genetics, Inc. is a privately held biotechnology company founded in 2007 to develop novel, function-based prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon and breast cancers. In early 2014, Metamark plans to commercialize ProMark™ – its prostate cancer prognostic test – through its Cambridge, Massachusetts CLIA-certified laboratory. For more information, please visit the company's Website at www.metamarkgenetics.com. Metamark™ and ProMark™ are trademarks of Metamark Genetics, Inc. SOURCE Metamark Genetics, Inc.